帕利哌酮治疗精神分裂症及其对生活质量的影响

目的探讨帕利哌酮对精神分裂症患者的疗效、安全性和生活质量的影响,为临床应用提供参考。方法将符合CCMD-Ⅲ精神分裂症诊断标准的住院患者99例随机分为:实验组48例给予帕利哌酮缓释片治疗,对照组51例给予齐拉西酮治疗,观察8周。采用阳性与阴性症状量表(PANSS)评定疗效,副反应量表(TESS)和相关实验室检查评定副反应,用生活质量综合评定量表(GQOLI-74)评定生活质量。结果治疗后两组患者各周PANSS比较差异无统计学意义。但实验组锥体外系症状(EPS)、肝功能异常患者明显少于对照组(χ2=4.01,4.99;P0.05),实验组病人社会功能改善、躯体功能恢复明显优于对照组(t=2.08,2.14;P0.05)。结论帕利哌酮在提高精神分裂症患者生活质量方面的效果明显优于齐拉西酮。

Effect of Paliperidone on Schizophrenia and Its Influence on Quality of Life

Objective To investigate the efficacy and safety of paliperidone on schizophrenia and its influence on quality of life ,and provide the reference for clinical application .Methods According to CCMD -III diagnostic criteria of schizophrenia , inpatients were randomly divided into two groups：48 cases in experimental group given paliperidone extended -release tablets treatment ,51 cases in the control group were given ziprasidone treatment .Observation was during for 8 weeks.The positive and negative syndrome scale （ PANSS） was used to assessed the efficacy,Tredtment Emergent Symptoms Scale（TESS）and related laboratory assessment for side effects,with the comprehensive quality of life scale （ GQOLI-74 ） assessing quality of life .Results After treatment , PANSS in two patients showed no statistical significante difference each week .But in the experimental group ,EPS and patients with abnormal liver function were significant-ly less than those of the control group （χ2 =4.01,4.99;P〈0.05）,the social function and recovery of physical function were more im-proved in experimental group than in control group （t=2.08,2.14;P〈0.05）.Conclusion The effect of paliperidone in improving the quality of life in patients with schizophrenia is superior to that of ziprasidone .